BPA Call HT001423A0016-HT001424F0061

Award Date 9/30/24
Potential Completion Date 9/30/24
Potential Value $18K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20889, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Prolacta Bioscience, Inc., a for-profit manufacturer, was awarded a Firm Fixed Price Blanket Purchase Agreement (BPA) call by the Defense Health Agency (DHA) to provide infant breast milk products in support of neonatal intensive care unit patients at military medical facilities. The potential value of this BPA call is $24,943.82, with a completion date of September 30, 2024. Prolacta Bioscience has held multiple previous contracts with the DHA and Department of the Army Medical Command to...
Prolacta Bioscience, Inc., a for-profit manufacturer of goods, has been awarded a Blanket Purchase Agreement (BPA) Call contract from the Defense Health Agency (DHA) to provide breastmilk supplementation products for neonatal intensive care unit (NICU) patients. The $13,022.86 firm fixed price contract has a performance period through September 30, 2024. Prolacta Bioscience, which holds two active indefinite delivery vehicles with the DHA valued at up to $250,000 and $1.75 million, delivers a...
This federal contract award to Prolacta Bioscience, Inc. is for the procurement of PROLACT+6 HMF, which are human milk-based nutritional products primarily for premature and critically ill infants in military medical facilities. The $3,254,150.28 firm fixed price contract, awarded by the Defense Health Agency (DHA), has an ultimate completion date of September 30, 2024. This award is part of three significant federal contract indefinite delivery vehicles (IDVs) held by Prolacta Bioscience with...
This contract was awarded to Prolacta Bioscience, Inc. by the Department of the Army Medical Command. The contract, valued at $150,000.00, is for the provision of human milk-based neonatal nutrition products to support premature and critically ill infants treated at military medical facilities. The contract is a Blanket Purchase Agreement (BPA) call, with a firm fixed price pricing type, and a performance period ending on September 30, 2022. Prolacta Bioscience, a manufacturer of goods, has...
This is a firm fixed price purchase order awarded by the Defense Health Agency (DHA) to Prolacta Bioscience, Inc. for $148,924.00. The contract is for PROLACT + 6, 30 ML 93901-30, which are human milk-based nutritional products for critically ill, premature infants in the neonatal intensive care unit (NICU). The contract has a period of performance from February 8, 2016 to February 7, 2017 and is designated as a Total Small Business set-aside. Prolacta Bioscience, a for-profit manufacturer,...
This federal contract award was issued by the U.S. Army Medical Command to Prolacta Bioscience, Inc., doing business as Prolacta Bioscience, a for-profit manufacturer of human milk-based nutritional products. The $351,630.75 firm fixed price delivery order is for "Fortified Human Breast Milk" and has an ultimate completion date of October 31, 2017. The contract is not set aside. Prolacta Bioscience has been awarded multiple prime contracts, primarily from the Defense Health Agency...
This firm fixed price contract was awarded by the Defense Health Agency to Prolacta Bioscience, Inc. to provide Prolacta's proprietary human milk-based nutritional products for use with infants in the neonatal intensive care unit (NICU) at Tripler Army Medical Center. The $15,536.12 contract is a call against a larger $250,000 single-award blanket purchase agreement for donor human milk and a $1.75 million single-award BPA for various human milk-based products to support military treatment...
This is a $96,228 firm fixed price purchase order awarded by the U.S. Army Medical Command to Prolacta Bioscience, Inc. for PROLACTA+6 H2MF 30 ML (93901-30) human milk-based nutritional products. The award has an ultimate completion date of December 31, 2018 and was made on October 11, 2018. Prolacta Bioscience is a for-profit manufacturer that specializes in human milk-based therapies for premature and critically ill infants in neonatal intensive care units. This contract is not associated with...
The Defense Health Agency, a component of the Department of Defense, awarded a $24,683.09 firm fixed price blanket purchase agreement call contract to Prolacta Bioscience, Inc. of Bassett, California. The contract is to provide breastmilk products to support neonatal intensive care unit patients from July 13, 2023 through September 30, 2023. As the leading government agency providing healthcare services to military service members, veterans, and their families, the Defense Health Agency utilizes...
This firm fixed price contract was awarded by the Defense Health Agency to Prolacta Bioscience, Inc. to provide breastmilk products for premature infants in the Neonatal Intensive Care Unit at Tripler Army Medical Center. The contract has a potential value of $13,444.03 and a completion date of September 30, 2023. No set-aside designation was used for this contract award. Prolacta Bioscience will deliver their breastmilk-based nutritional products to support premature infants in the NICU at...
  • HT001423A0016
    Blanket Purchase Agreement
  • HT001423A0016-HT001424F0061
    BPA Call

Prolacta Bioscience, Inc., a for-profit manufacturer of goods, has been awarded a Blanket Purchase Agreement (BPA) Call contract by the Defense Health Agency (DHA) to provide a variety of human milk-based nutritional products, including donor human milk, pre-natal formulas, breastmilk, and supplements, to support premature and critically ill infants in military medical facilities. The contract, valued at $18,091.00, has a firm fixed price pricing type and a completion date of September 30, 2024. This award is part of two larger indefinite delivery vehicles held by Prolacta Bioscience with DHA, valued at $250,000 and $1.75 million respectively, which provide human milk-based therapies to the military health system. No set-aside designation was used for this contract.

Generated 6/4/24, 10:02 AM